Informations générales (source: ClinicalTrials.gov)
Observation of Platelets in Primary and Secondary Tumors of the Central Nervous System and Association With Survival: a Prospective Cohort Study (Platon)
Interventional
N/A
Fondation Ophtalmologique Adolphe de Rothschild (Voir sur ClinicalTrials)
octobre 2022
janvier 2028
29 juin 2024
Platelets are primarily known for their central role in primary hemostasis. However, they
are increasingly recognized for their participation in various non-hemostatic processes,
such as cancer progression and clinical expression. Experimental and clinical data
indicate that the involvement of platelets in the pathophysiology of cancer goes far
beyond the realm of cancer-associated thrombosis.
Several experimental studies have shown that platelets can promote the metastatic process
by various mechanisms. However, while it has been shown in vitro that direct contact with
platelets initiates tumor cells for metastasis, it remains unclear whether such contacts
occur in solid tumors. In addition to their ability to promote metastasis, platelets have
been shown to stimulate angiogenesis and play a crucial role in lymphangiogenesis.
Considering that blood vessels, lymphatics and immune cells are major components of the
tumor ecosystem, our hypothesis is that platelets contribute to the development and / or
regulation of the tumor microenvironment. This is because platelets stabilize tumor blood
vessels by permanently repairing vascular damage caused by immune cells infiltrating
tumors. Targeting platelets destabilizes tumor vessels, causing intra-tumor hemorrhage,
which allows intra-tumor accumulation of intravenously administered anti-tumor drugs such
as paclitaxel and improves their efficacy.
Studies have also reported the role of platelets in several pathogenic mechanisms of
cancer: thrombocytosis is a paraneoplastic syndrome which suggests a poor prognosis in
patients with solid tumors; a negative correlation between the platelet count and the
response to chemotherapy has been reported in several types of cancer; histological
analyzes of esophageal cancer suggested a possible association between the presence of
platelets in the tumor stroma and the level of tumor lymphangiogenesis and lymphovascular
invasion; finally, a recent study reported the expression of one of the main targets of
immunotherapies, PD-L1, on the platelets of patients suffering from different types of
solid cancers.
All of these data support our hypothesis that platelets are components and / or
regulators of the tumor microenvironment and therefore potential targets for the
improvement of anti-tumor therapies. In this context, the objectives of our project are
to determine whether platelets are components of the microenvironment of tumors of the
central nervous system, and to study the possible correlations between the intratumoral
presence of platelets and the evolution of patients with central nervous system tumors
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FONDATION A. DE ROTHSCHILD | Pierre BOURDILLON | 21/06/2024 13:34:09 | Contacter | ||
Critères
Tous
Inclusion Criteria:
- Patient to undergo excision or biopsy of a brain or medullary tumor
- Patient over 18 years old
- Express consent to participate in the study
- Affiliate member of the Social Security system
- Patient to undergo excision or biopsy of a brain or medullary tumor
- Patient over 18 years old
- Express consent to participate in the study
- Affiliate member of the Social Security system
- Tumor sample volume not allowing the performance of additional analyzes
- Patient benefiting from a legal protection measure
- Pregnant or breastfeeding woman